



# Synergy Pharmaceuticals, Inc.

## Corporate Profile - August, 2010

### STATISTICS

OTC BB: SGYP.OB  
 Fiscal Year: Dec. 31  
 Common shares o/s (mm): 90

### COMPANY OVERVIEW

Headquarters: New York, NY  
 Transfer Agent: StockTrans, Inc.  
 Auditors: BDO Seidman, LLP

### BUSINESS FOCUS

Synergy is focused on drugs to treat gastrointestinal disorders and diseases.

### MANAGEMENT

#### Gary S. Jacob, Ph.D. President & CEO

25+ years experience in drug discovery and development at Monsanto, G.D. Searle, Oxford University, Callisto Pharmaceuticals, Synergy. Ph.D., U. Wisconsin - Madison.

#### Gabriele M. Cerrone Chairman

Founder of number of biotechnology and diagnostic companies, including Fermavir Pharmaceuticals (now part of Inhibitex, Inc.), TrovaGene, Inc. and Callisto Pharmaceuticals, Inc. Managing partner of Panetta Partners Ltd, a Colorado limited partnership.

#### Kunwar Shailubhai, Ph.D. Chief Scientific Officer

20+ years experience in drug discovery and development at NIH, G.D. Searle, Callisto, Synergy. Ph.D., University of Baroda, India; MBA from U. Missouri.

**Craig C. Talluto, Ph.D., Executive Director, Clinical Development.** Over 10 years of experience at Amgen, Roche and Kos, Ph.D., University of Miami, FL.

**Bernard F. Denoyer, MBA, CPA, SVP, Finance.** Over 25 years experience in META Group, Envionetics, Gartner Group and Ernst & Young. MBA, Columbia University.

### ABOUT SYNERGY PHARMACEUTICALS

Synergy Pharmaceuticals, Inc. (SGYP.OB), a public, development-stage biopharmaceutical company, is focused on the development of drugs to treat gastrointestinal (GI) conditions and diseases. The Company is located in New York City, and also maintains a research laboratory in Doylestown, PA supporting Synergy's research and drug development activities.

Synergy's drug development program and patent estate are based on a class of synthetic peptides designed to mimic uroguanylin, a human hormone that plays a key role in GI physiology.

Plecanatide (formerly SP-304), and SP-333, Synergy's two drugs in development to treat GI disorders and ulcerative colitis (UC), respectively, were discovered and developed in-house by Synergy scientists.

Plecanatide, a guanylyl cyclase C (GC-C) receptor agonist, is currently completing a Phase IIa clinical trial in chronic constipation (CC) patients, and is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C). SP-333, Synergy's second GC-C receptor agonist, is being developed to treat ulcerative colitis (UC), an inflammatory bowel disease.


### PIPELINE

#### Plecanatide

Plecanatide is currently completing a Phase IIa 14-day, repeated-oral-dose, clinical trial in CC patients, and is scheduled to enter a Phase IIb 28-day trial in CC patients in 1Q2011, and a Phase IIb 90-day trial in IBS-C patients in 2Q2011.

#### SP-333

SP-333, a GC-C receptor agonist, is in preclinical development to treat UC. A Phase I trial is planned for 1Q2011.



## DEVELOPMENT PROGRAMS

### Plecanatide Development Program:

- **Chemistry and biology:** Plecanatide is an analog of the natural gastrointestinal peptide uroguanylin, a key regulator of intestinal function. Plecanatide works locally in the GI tract by activating the GC-C receptor, a receptor on the inside lining of the intestine, promoting fluid and ion transport in the GI tract. The drug, administered orally, acts locally in the gut and shows virtually no systemic absorption into the bloodstream, suggesting that the drug is likely to display an excellent safety profile in ensuing trials.
- **Development:** Plecanatide completed a single-dose Phase I clinical trial in volunteers in late 2008. A Phase IIa randomized, placebo-controlled, 14-day, repeated-oral-dose trial in CC patients was initiated in early 2010, and the company plans to follow this trial with Phase 2b trials in CC and IBS-C in 2011.
- **Market opportunity:** CC and IBS-C are functional GI disorders that afflict millions of sufferers worldwide. Currently, there is only one product approved for these indications in the US.

#### **Chronic Constipation (CC)**

CC is a common GI disorder affecting up to 26 million Americans, roughly 5 million of whom have severe symptoms necessitating relief. The incidence of CC is similar in other developed countries, including Europe and Japan. Patients with CC often experience hard stools, straining during bowel movements and insufficient bowel movements per week. People with CC typically experience serious discomfort, adversely affecting their ability to work and their quality of life.

#### **Irritable Bowel Syndrome (IBS)**

Up to one in six adults experience IBS in the US, a condition marked by disturbed bowel function and abdominal pain. IBS patients fall into three categories with different symptoms; diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), and mixed or alternating disorder (IBS-M). The number of individuals in each category is about 33% of the total number of IBS patients. An estimated 10 million people in the US suffer from IBS-C, with about 2.5 million experiencing the severe form of the condition. IBS (all forms) accounts for approximately 12% of all adult visits to primary care physicians in the US. An equivalent amount of people, roughly 10 million, suffer from the condition in the EU.

### SP-333 Development Program:

- **Chemistry and biology:** SP-333, a second-generation GC-C receptor agonist based on uroguanylin, is designed as our lead drug candidate to treat UC, an inflammatory bowel disease.
- **Development:** SP-333 is currently in pre-clinical development and Synergy plans to file an Investigational New Drug application (IND) to treat UC in late 2010, and initiate a trial in volunteers in early 2011.

## RECENT NEWS

March 19, 2010

Synergy Pharmaceuticals Initiates Phase 2a Clinical Trial of SP-304 (Plecanatide) in Patients with Chronic Constipation

January 22, 2010

Synergy Pharmaceuticals to Present at the 8th Annual Bio-Partnering North America (BPN) Conference in Vancouver, BC, Canada

December 11, 2009

Synergy Pharmaceuticals Raises \$8.6 Million in Common Stock Financing

October 8, 2009

Synergy Pharmaceuticals Announces Appointment of Dr. Alan F. Joslyn to Board of Directors

October 5, 2009

Synergy Pharmaceuticals to Present at the 17th Annual Bio-Partnering Europe Conference in London, UK

July 7, 2009

Synergy Pharmaceuticals Raises \$7.09 Million in Common Stock Financing

May 26, 2009

Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorders at Upcoming Conference

## CONTACT INFORMATION

### Corporate office:

Synergy Pharmaceuticals, Inc.  
420 Lexington Avenue, Suite 1609  
New York, NY 10170, USA.

Tel: +1-212-297-0020

Fax: +1-212-297-0019

Web: [www.synergypharma.com](http://www.synergypharma.com)

For more information, please contact Gary S Jacob, Ph.D., CEO:  
[gjacob@synergypharma.com](mailto:gjacob@synergypharma.com)  
Tel: +1-212-297-0020